Deudimethyltryptamine

Deudimethyltryptamine
Clinical data
Other namesHLP004; HLP-004; CYB004; CYB-004; Deuterated dimethyltryptamine; Deuterated DMT; dDMT; D-DMT; DMT-d10; Decadeutero-DMT
Routes of
administration
Inhalation, intravenous
Drug classSerotonergic psychedelic; Serotonin receptor agonist
Pharmacokinetic data
Elimination half-life37–40 minutes
Duration of action~40 minutes
Identifiers
  • 1,1,2,2-tetradeuterio-2-(1H-indol-3-yl)-N,N-bis(trideuteriomethyl)ethanamine
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC12H16N2
Molar mass188.274 g·mol−1
3D model (JSmol)
  • [2H]C([2H])([2H])N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])C1=CNC2=CC=CC=C21
  • InChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3/i1D3,2D3,7D2,8D2
  • Key:DMULVCHRPCFFGV-TXNVYZHYSA-N

Deudimethyltryptamine (INNTooltip International Nonproprietary Name; developmental code names HLP004 and CYB004), also known as deuterated dimethyltryptamine (dDMT) or as DMT-d10, is a psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT) which is under development for the treatment of generalized anxiety disorder, anxiety disorders, and depressive disorders. It is administered by inhalation or intravenous injection. The drug is a deuterated isotopologue of DMT with altered pharmacokinetics.

Interactions

Pharmacology

The pharmacodynamic profile of deudimethyltryptamine, including its interactions with serotonin receptors and its effects in animals, is similar to that of DMT. As with DMT, deudimethyltryptamine is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals. However, deudimethyltryptamine, due to its deuteration, is more resistant to metabolism than DMT and shows a longer elimination half-life (by 2.5- to 2.9-fold) and slower clearance (by 38 to 55%) in animals. The brain to plasma ratio of deudimethyltryptamine was also increased (by 30%) relative to DMT, indicating slightly greater central permeability as well.

The pharmacokinetics and effects of deudimethyltryptamine in humans have been studied and compared with those of DMT. Its elimination half-life was 37 to 40 minutes and its duration was approximately 40 minutes. For comparison, the half-life of DMT in humans has been reported to be 9 to 12 minutes (range 5–19 minutes). Deudimethyltryptamine produced more robust psychedelic effects than DMT at lower concentrations. Additional details on the pharmacokinetics of deudimethyltryptamine in humans have also been reported.

Chemistry

Analogues

Other deuterated drugs related to deudimethyltryptamine or DMT-d10 include the deuterated DMT analogue SPL028 (D2-DMT; α,α-dideutero-DMT), the deuterated psilocin analogue deupsilocin (HLP003; CYB003; d10-psilocin), and the deuterated phenethylamine HLP005 (CYB005).

Research

Deudimethyltryptamine is under development by Helus Pharma (formerly Cybin). It is under development for the treatment of generalized anxiety disorder, anxiety disorders, and depressive disorders. As of July 2026, deudimethyltryptamine is in phase 2 clinical trials for generalized anxiety disorder and phase 1 trials for anxiety disorders and depressive disorders. It was also under development for the treatment of substance-related disorders and other psychiatric disorders, but development for these indications was discontinued.

See also